P/B
6,7
Novartis
Novartis develops and manufactures innovative drugs. Key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
Novartis develops and manufactures innovative drugs. Key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
$276.5B
Market Cap • 9/25/2026
1996
(30 years)
Founded
1996
(30 years ago)
IPO
NYSE
Listing Exchange
Switzerland
Country
Valuation
P/S
4,9
P/EBITDA
12,3
P/OCF
15
P/FCF
16,5
P/E
21,9
BVPS
21,6
EPS
6,6
Market Cap
Market Cap
276,5B
EV
318,2B
EV/Revenue
5,6
EV/EBITDA
14,1
EV/EBIT
18,6
Payout
Dividend Per Share
4,7
Dividend Yield
3,3%
Buyback Yield
2,5%
Total Yield
5,7%
Dividend Yield 5Y
2,7%
Payout
71,1%
Retained Earnings
40,9B
Profitability
Gross Margin
74,7%
EBITDA Margin
39,8%
EBIT Margin
30,2%
Net Margin
22,5%
D&A/EBITDA
0%
R&D/Revenue
20,6%
Capex/Revenue
2,9%
Capex/D&A
30%
Capex/OCF
8,9%
SBC/OCF
6,2%
% PPE
10,1%
% Goodwill
21,9%
ROE
30,4%
ROIC
14,7%
Growth
CAGR Revenue 5Y
1,9%
CAGR Op. Income 5Y
9,3%
CAGR Net Income 5Y
7,2%
CAGR EPS 5Y
10,9%
CAGR OCF 5Y
6,5%
Leverage
N.D./EBITDA
1,8
Debt/Equity
0%
Current Ratio
0,9
Quick Ratio
0,6
Interest Coverage
1230,4%
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!